Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.

NCT01270945 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Patients Undergoing Repeat Peripheral Artery Revascularization

Interventions

DRUG: CV-18C3
PROCEDURE: Standard of Care

Sponsor

Janssen Research & Development, LLC